

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



UNIVERSAL HEALTH INTERNATIONAL GROUP HOLDING LIMITED
大健康國際集團控股有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 2211)

**SUPPLEMENTAL ANNOUNCEMENT IN RELATION TO SUBSCRIPTIONS
OF NEW SHARES UNDER GENERAL MANDATE**

Reference is made to the announcement of the Company dated 23 May 2022 in relation to the Subscriptions (the “**Announcement**”). Unless otherwise defined, the capitalized terms used herein shall have the same meanings as defined in the Announcement.

The Board wishes to provide the Shareholders and potential investors of the Company with additional information in relation to the Announcement.

USE OF PROCEEDS FROM THE SUBSCRIPTIONS

As disclosed in the Announcement, the gross proceeds and net proceeds from the Subscriptions are expected to be approximately HK\$13.9 million and HK\$13.6 million respectively. The Company intends to apply such net proceeds for general working capital for the Group.

Since many countries were adversely affected and China is facing challenges to combat the outbreak of Omicron. Under the zero-tolerance strategy, the local governments in the PRC implemented stringent measures to control the epidemic. In light of the above, the intended use of the proceeds would mainly focus on the following aspects:

The Company intends to apply such net proceeds for general working capital for the Group to secure its operating cash flow, including paying off costs incurred from (i) store operation and (ii) replenishing the Group’s inventory of anti-epidemic items.

Specifically, regarding the item (ii) disclosed above, the Company wishes to prepare for the future outbreak of Covid-19 and stock up anti-epidemic items in advance which will be essential for combating the Covid-19 by the general public, take for instance disinfection products and products for improving immune system. The Board is of the view that replenishing such products can increase the competitiveness and fulfil social responsibility of the Group.

Estimated timeline

The estimated net proceeds from the Subscriptions after deduction of expenses, will amount to approximately HK\$13.6 million, and are intended to be applied in the second half of 2022 as follows:

Expected time of usage	Approximate amount of net proceeds allocated	Intended application
June	HK\$5,000,000	Replenishing inventory of anti-epidemic items
July	HK\$5,000,000	Replenishing inventory of anti-epidemic items
August	HK\$3,600,000	Replenishing inventory of anti-epidemic items; and Paying off rental expenses of approximately HK\$2.5 million

Save as disclosed above, all other information and contents set out in the Announcement remain unchanged.

As Completion is subject to the satisfaction of certain conditions precedent, the Subscriptions may or may not proceed. Shareholders and potential investors are advised to exercise caution when dealing in the Shares.

By Order of the Board
Universal Health International Group Holding Limited
Jin Dongtao
Chairman and executive Director

Hong Kong, 1 June 2022

As at the date of this announcement, the Board comprises four executive directors, namely, Mr. Jin Dongtao, Mr. Jin Dongkun, Mr. Zhao Zehua and Mr. Chu Chuanfu and three independent non-executive directors, namely, Mr. Cheng Sheung Hing, Ms. Chiang Su Hui Susie and Mr. Zou Haiyan.